Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 429 -0.02%
19 May 3:21 p.m.
cohance.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 16,427 Cr.
  • Current Price ₹ 429
  • High / Low ₹ 1,180 / 267
  • Stock P/E 83.2
  • Book Value ₹ 102
  • Dividend Yield 0.00 %
  • ROCE 8.35 %
  • ROE 7.04 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 4.19 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.7% over last 3 years.
  • Debtor days have increased from 80.9 to 110 days.
  • Working capital days have increased from 122 days to 175 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty MNC Nifty500 Shariah

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
369.36 347.55 231.05 219.82 252.93 488.08 603.77 676.23 840.42 549.31 555.57 544.55 619.12
197.50 180.59 133.09 153.74 179.58 362.98 398.40 438.86 611.20 437.30 434.62 449.20 520.44
Operating Profit 171.86 166.96 97.96 66.08 73.35 125.10 205.37 237.37 229.22 112.01 120.95 95.35 98.68
OPM % 46.53% 48.04% 42.40% 30.06% 29.00% 25.63% 34.01% 35.10% 27.27% 20.39% 21.77% 17.51% 15.94%
11.40 10.67 19.84 14.34 17.05 19.41 16.19 21.56 -3.73 6.07 15.60 1.30 -18.35
Interest 5.03 1.15 0.50 2.16 2.30 10.20 9.61 10.80 10.45 10.18 8.76 9.11 9.19
Depreciation 12.02 12.54 11.89 12.79 17.25 31.28 37.79 43.56 54.17 45.14 44.02 46.94 51.23
Profit before tax 166.21 163.94 105.41 65.47 70.85 103.03 174.16 204.57 160.87 62.76 83.77 40.60 19.91
Tax % 25.41% 26.44% 24.51% 28.59% 24.67% 26.85% 20.62% 24.97% 27.18% 26.07% 20.75% 28.52% 58.26%
123.97 120.59 79.56 46.75 53.37 75.37 138.24 153.48 117.15 46.40 66.39 29.02 8.31
EPS in Rs 4.87 4.74 3.13 1.84 2.10 2.96 5.44 6.01 4.73 1.28 1.94 0.96 0.51
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
378 834 1,010 1,320 1,340 1,051 1,198 2,269
206 449 567 738 766 645 822 1,842
Operating Profit 172 385 443 582 574 406 375 427
OPM % 45% 46% 44% 44% 43% 39% 31% 19%
1 66 68 133 46 62 58 5
Interest 3 23 12 9 13 7 12 37
Depreciation 12 24 32 39 48 55 77 187
Profit before tax 158 405 468 668 560 406 344 207
Tax % 31% 22% 23% 32% 27% 26% 23% 27%
109 317 362 454 411 300 265 150
EPS in Rs 12.45 14.23 17.83 16.16 11.80 10.52 4.68
Dividend Payout % -0% 20% 14% 28% 37% -0% -0% -0%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 19%
TTM: 89%
Compounded Profit Growth
10 Years: %
5 Years: -11%
3 Years: -21%
TTM: -17%
Stock Price CAGR
10 Years: %
5 Years: -3%
3 Years: -3%
1 Year: -60%
Return on Equity
10 Years: %
5 Years: 16%
3 Years: 11%
Last Year: 7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital -0.00 13 25 25 25 25 25 38
Reserves 578 832 1,155 1,502 1,710 2,025 1,671 3,873
83 186 143 97 70 65 279 400
123 142 151 205 160 138 1,056 1,418
Total Liabilities 783 1,173 1,474 1,830 1,966 2,254 3,031 5,730
271 357 441 534 663 670 1,713 3,373
CWIP 111 102 96 30 165 179 256 173
Investments 7 338 542 598 536 904 337 529
394 376 395 667 601 501 725 1,655
Total Assets 783 1,173 1,474 1,830 1,966 2,254 3,031 5,730

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
50 407 383 330 457 358 288 368
-65 -413 -311 -136 -195 -362 -253 -255
26 7 -76 -156 -242 -14 3 -165
Net Cash Flow 11 1 -5 37 20 -18 38 -51
Free Cash Flow -6 304 272 255 171 307 132 169
CFO/OP 49% 128% 111% 88% 105% 115% 99% 102%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 142 51 37 65 30 46 87 110
Inventory Days 556 278 243 259 279 268 199 310
Days Payable 190 113 100 97 63 49 96 157
Cash Conversion Cycle 509 217 180 228 247 265 190 263
Working Capital Days 205 64 56 108 99 115 74 175
ROCE % 50% 40% 41% 32% 19% 15% 8%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
Patented Commercial Molecules (Pharma CDMO)
Number

Log in to view insights

Please log in to see hidden values.

Login
Phase III Molecules (Pharma CDMO Pipeline)
Number
USFDA Approved Manufacturing Sites
Number
ANDA Portfolio (Partnered and Owned)
Number
Phase III Intermediates
Number
Total Active Projects Pipeline (CDMO)
Number
Working Capital Days
Days
Total Manufacturing Capacity (Commercial)
kL
DMF Filings (Yearly)
Number
Niche Tech Contribution to CDMO Revenue
Percentage
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

9 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41% 57.49% 57.49% 57.49%
9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23% 6.51% 6.01% 5.59%
10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40% 20.81% 21.57% 21.79%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95% 15.16% 14.91% 15.11%
No. of Shareholders 72,16773,71570,05268,93265,77769,33784,21086,32580,91075,28481,87785,230

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls